Recombinant antibodies have become a standard component of research, diagnostics, and therapy. In the development of recombinant antibodies – irrespective of the final format – a monovalent construct is virtually always the first protein to be tested. This is due to the fact that essentially all selection systems use such formats, and that the periplasmic production of scFv and Fab fragments has now become standard. Nonetheless, some tasks require an increase of the avidity to the respective antigens, antibody, as well as the fragment size. A convenient way to rather quickly achieve both is by fusing a hinge region followed by a dimerizing or oligomerizing structure to the C-terminus of the antibody fragment, creating the so-called “miniantibodies”. Compared to other available bivalent or bispecific formats, miniantibodies distinguish themselves by their rotational freedom and flexibility, being similar to full-length antibodies. This protocol describes the modular conversion of scFv fragments into miniantibodies, resulting in a final multimerized structure with two or four binding sites, and we present different self-associating domains suitable for this task. Additionally, we also provide information on their production and discuss how to improve the yield of soluble antibody fragments.
Phosphate buffered saline
Single-chain Fv fragment
Super broth media
This chapter is based on the original work of Peter Pack, Jörg Willuda and Susanne Kubetzko, with subsequent contributions from Kerstin Blank and Barbara Klinger.
- Ge L, Knappik A, Pack P, Freund C, Plückthun A (1995) Expressing antibodies in Escherichia coli. In: Borrebaeck C (ed) Antibody engineering, 2nd ed. Oxford University Press, London, pp 229–236Google Scholar
- Horn U, Strittmatter W, Krebber A, Knüpfer U, Kujau M, Wenderoth R, Müller K, Matzku S, Plückthun A, Riesenberg D (1996) High volumetric yields of functional dimeric miniantibodies in Escherichia coli, using an optimized expression vector and high-cell-density fermentation under non-limited growth conditions. Appl Microbiol Biotechnol 46:524–532PubMedCrossRefGoogle Scholar
- Kellner C, Bruenke J, Stieglmaier J, Schwemmlein M, Schwenkert M, Singer H, Mentz K, Peipp M, Lang P, Oduncu F, Stockmeyer B, Fey GH (2008) A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells. J Immunother 31:871–884PubMedCrossRefGoogle Scholar
- Kügler M, Stein C, Schwenkert M, Saul D, Vockentanz L, Huber T, Wetzel SK, Scholz O, Plückthun A, Honegger A, Fey GH (2009) Stabilization and humanization of a single-chain Fv antibody fragment specific for human lymphocyte antigen CD19 by designed point mutations and CDR-grafting onto a human framework. Protein Eng Des Sel 22:135–147PubMedCrossRefGoogle Scholar
- Lindner P, Plückthun A (2001) Miniantibodies. In: Kontermann R, Dübel S (eds) Antibody engineering. Springer, Berlin, pp 637–647Google Scholar
- Pack P, Kujau M, Schroeckh V, Knüpfer U, Wenderoth R, Riesenberg D, Plückthun A (1993) Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell density fermentation of Escherichia coli. Biotechnology (NY) 11:1271–1277Google Scholar
- Plückthun A, Krebber A, Krebber C, Horn U, Knüpfer U, Wenderoth R, Nieba L, Proba K, Riesenberg D (1996) Producing antibodies in Escherichia coli: Fom PCR to fermentation. In: McCafferty J, Hoogenboom H (eds) Antibody engineering: a practical approach. IRL Press, Oxford, pp 203–252Google Scholar
- Willuda J, Honegger A, Waibel R, Schubiger PA, Stahel R, Zangemeister-Wittke U, Pluckthun A (1999) High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment. Cancer Res 59:5758–5767PubMedGoogle Scholar